A recent study published in Diabetology International highlighted the role of tirzepatide in reducing eating behavior and improving quality of life in patients with type 2 diabetes mellitus. The study aimed to determine the change in eating behavior in patients with T2DM on treatment with tirzepatide.

A total of 60 patients who had been on tirzepatide for 3 months were included in the study. For 3 months after the initiation of tirzepatide, changes in HbA1c levels and body weight were observed. A questionnaire survey that included eating behavior (Eating Behavior Questionnaire) and diet-related quality of life (DDRQOL) was conducted.

In the first month of administration, a reduction in HbA1c levels from 7.40 ± 1.58% at the start to 6.78 ± 0.99% after 3 months was observed. A decrease in body weight from 80.7 ± 13.2 kg at the start to 78.3 ± 12.9 kg after 3 months was also found. A reduction in total Eating Behavior Questionnaire score was also seen from 52.9 ± 10.9 points to 47.7 ± 9.9 points after 3 months.

Between weight variations (r = 0.363, p = 0.005) and the total score of the Eating Behavior Questionnaire, a strong positive correlation was observed. "Satisfaction with diet" changed from 75.3 ± 14.5 points at the start to 73.9 ± 14.8 points, which was also found to be changed regarding scores by subscales of DDRQOL after 3 months.

An increase in "Burden of diet therapy"  from 50.8 ± 14.9 points to 56.1 ± 15.9 points was seen, while the  "Perceived merits of diet therapy"  was found to be changed from 57.9 ± 13.9 points to 61.8 ± 11.2 points.